Alzheimer’s Disease: Recent Developments in Pathogenesis, Diagnosis, and Therapy
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Physiology and Pathology".
Deadline for manuscript submissions: 30 September 2024 | Viewed by 51
Special Issue Editors
Interests: Alzheimer's disease; immunogenetics; HLA typing; neurodegenerative diseases
Special Issues, Collections and Topics in MDPI journals
Interests: Alzheimer's disease; autoimmunity; immunogenetics; neurodegenerative diseases; neuroinflammation; multiple sclerosis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Alzheimer’s disease (AD) is the most common neurodegenerative disorder in elderly individuals, characterized by a complex pathogenic and clinical profile involving neuronal dysfunction, progressive brain atrophy, and cognitive decline. As the leading cause of dementia worldwide, with approximately 50 million cases, AD poses a substantial medical and socio-economic burden. Despite significant advancements in recent decades, the processes leading to AD-related pathology remain poorly understood. Ongoing efforts to unravel the key cellular and molecular players involved in the development of amyloid and tau pathology, neuroinflammation, neurodegeneration, and other abnormalities offer promising prospects for the identification of new screening and diagnostic biomarkers, as well as the development of novel therapeutic strategies.
In this Special Issue, we aim to publish review and original research articles on the etiology, pathogenesis, diagnostics, and therapy of AD. We invite submissions addressing a broad range of topics including, but not limited to, the following aspects of AD:
- Genetic, epigenetic, environmental, and lifestyle risk factors for AD.
- The role of the immune system, oxidative stress, mitochondrial dysfunction, and endocrine, metabolic, and other alterations in the development of AD.
- The potential link between the gut microbiome and AD.
- Novel biomarkers for AD diagnostics.
- Emerging therapeutic approaches.
We welcome contributions that shed light on these areas and advance our understanding of Alzheimer’s disease.
Dr. Ivana Shawkatová
Dr. Juraj Javor
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Alzheimer’s disease
- biomarkers
- epigenetics
- genetics
- genomics
- immune mediators
- neurodegeneration
- neuroinflammation
- proteomics
- risk factors
- therapy
- transcriptomics
